This legislation amends the Social Security Act to establish Medicare coverage for treatments specifically for dialysis-related amyloidosis . It defines these covered treatments as any item or service approved by the Food and Drug Administration for this condition, furnished within a dialysis facility, along with necessary adjunct supplies and services. A crucial provision ensures these treatments are explicitly included as covered medical services under Medicare. Significantly, the bill mandates that these treatments be excluded from standard renal dialysis services for payment calculations. Instead, Medicare will provide separate payment at 100 percent of the reasonable charges for these specific items and services, preventing them from being bundled into existing prospective payment systems.